Surface Oncology: Gains on Merck tie-up, surprise Q4 profit

Surface Oncology

09/03/2021 12:28

** Shares of cancer drug developer Surface Oncology Inc
 SURF.O  rise nearly 6% to $7.80 premarket
    ** SURF to partner with drugmaker Merck & Co  MRK.N  in a
clinical trial to evaluate the safety and efficacy of a
combination of co's SRF388 and MRK's Keytruda in treating
certain forms of cancer  urn:newsml:reuters.com:*:nGNXc5S9y8
    ** Co's Q4 EPS $1.56, beats estimates of a loss of 5 cents,
according to Refinitiv data  urn:newsml:reuters.com:*:nGNX3kXFNL
    ** SURF set for its best day in more than one week, down
20.3% YTD

 (Reporting by Ambar Warrick in Bengaluru)
 ((Ambar.Warrick@thomsonreuters.com; +91-80-6182-2837; Reuters
Messaging: ambar.warrick.thomsonreuters.com@reuters.net;
Twitter: @AmbarWarrick))